bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to
developing potentially transformative gene therapies for severe genetic
diseases and T cell-based immunotherapies, today announced that members
of the management team will present at the following upcoming investor
conferences:
-
The Cowen and Company 36th Annual Health Care Conference on
Wednesday, March 9, 2016, at 10:00 a.m. ET at the Boston Marriott
Copley Place in Boston.
-
The 28th Annual ROTH Conference on Monday, March 14, 2016,
at 2:30 p.m. PT at the Ritz-Carlton, Laguna Niguel in Orange County,
CA.
-
The Alliance for Regenerative Medicine’s 4th Annual Cell &
Gene Investor Day on Tuesday, March 22, 2016, at 1:55 p.m. ET at the
Metropolitan Club in New York City.
To access the live webcasts of bluebird bio’s presentations, please
visit the “Calendar of Events” page within the Investors and Media
section of the bluebird bio website at http://investor.bluebirdbio.com.
Replays of the webcasts will be available on the bluebird bio website
for 90 days following the conferences.
About bluebird bio, Inc.
With its lentiviral-based gene therapies, T cell immunotherapy expertise
and gene editing capabilities, bluebird bio has built an integrated
product platform with broad potential application to severe genetic
diseases and cancer. bluebird bio’s gene therapy clinical programs
include its Lenti-D™ product candidate, currently in a Phase 2/3 study,
called the Starbeam Study, for the treatment of cerebral
adrenoleukodystrophy, and its LentiGlobin® BB305 product candidate,
currently in three clinical studies for the treatment of
transfusion-dependent ß-thalassemia, also known as ß-thalassemia major,
and severe sickle cell disease. bluebird bio’s oncology pipeline is
built upon the company’s leadership in lentiviral gene delivery and T
cell engineering, with a focus on developing novel T cell-based
immunotherapies, including chimeric antigen receptor (CAR T) and T cell
receptor (TCR) therapies. bluebird bio’s lead oncology program, bb2121,
is an anti-BCMA CAR T program partnered with Celgene. bb2121 is
currently being studied in a phase 1 trial for the treatment of
relapsed/refractory multiple myeloma. bluebird bio also has discovery
research programs utilizing megaTALs/homing endonuclease gene editing
technologies with the potential for use across the company’s pipeline.
bluebird bio has operations in Cambridge, Massachusetts, Seattle,
Washington, and Paris, France.
LentiGlobin and Lenti-D are trademarks of bluebird bio, Inc.
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding bluebird bio’s existing product candidates and
research programs. Any forward-looking statements are based on
management’s current expectations of future events and are subject to a
number of risks and uncertainties that could cause actual results to
differ materially and adversely from those set forth in or implied by
such forward-looking statements. These risks and uncertainties include,
but are not limited to, risks that the preliminary results from our
clinical trials will not continue or be repeated in our ongoing clinical
trials, the risk that previously conducted studies involving similar
product candidates will not be repeated or observed in ongoing or future
studies involving current product candidates, the risk of cessation or
delay of any of the ongoing or planned clinical studies and/or our
development of our product candidates, the risk of a delay in the
enrollment of patients in our clinical studies, the risk that our
collaboration with Celgene will not continue or will not be successful,
and the risk that any one or more of our product candidates will not be
successfully developed and commercialized. For a discussion of other
risks and uncertainties, and other important factors, any of which could
cause our actual results to differ from those contained in the
forward-looking statements, see the section entitled “Risk Factors” in
our most recent quarterly report on Form 10-Q, as well as discussions of
potential risks, uncertainties, and other important factors in our
subsequent filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release, and
bluebird bio undertakes no duty to update this information unless
required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160302005747/en/
Copyright Business Wire 2016